# US 9,040,584 B2 · Compositions for topical delivery of prostaglandins to subcutaneous fat > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 9,040,584 B2 - Document ID: US9040584B2 - Status: Granted - Kind: B2 - Application number: 14/575,873 - Filed: 2014-12-18 - Published: 2015-04-16 - Granted: 2015-05-26 - Earliest claimed: 2013-05-10 - Assignees: Topokine Therapeutics, Inc. - Applicants: Topokine Therapeutics, Inc. - Inventors: Michael S. Singer; Murat V. Kalayoglu - Web page: https://patentgrep.com/patent/US9040584B2 ## CPC - A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters - A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)} - A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)} - A61K 31/23: of acids having a carboxyl group bound to a chain of seven or more carbon atoms - A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha - A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) - A61P 3/04: Anorexiants; Antiobesity agents - A61P 27/02: Ophthalmic agents - A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract Described herein are compositions comprising a prostaglandin FP receptor agonist (PFPRA) compound and a fatty acid ester (e.g., isopropyl myristate), optionally comprising an ointment base such as a hydrocarbon base (e.g., petroleum jelly) and/or an organic alcohol (e.g., propylene glycol), that, when topically applied to the skin, locally delivers a therapeutically effective amount of the PFPRA compound to subcutaneous fat under the skin, and methods of preparation. The therapeutic effect is, for example, reduction of the subcutaneous fat under the skin. Further provided are methods of reducing body fat in a subject comprising topically administering the composition to the subject. ## Claims ### Claim 1 A composition comprising latanoprost, isopropyl myristate, and petroleum jelly. ### Claim 2 (depends on 1) The composition of claim 1, consisting essentially of latanoprost, isopropyl myristate, and petroleum jelly. ### Claim 3 (depends on 1) The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w. ### Claim 4 (depends on 3) The composition of claim 3, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w. ### Claim 5 (depends on 2) The composition of claim 2, wherein the latanoprost concentration is between about 0.01% and about 0.5% w/w. ### Claim 6 (depends on 5) The composition of claim 5, wherein the latanoprost concentration is between about 0.03% and about 0.1% w/w. ### Claim 7 (depends on 1) The composition of claim 1, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w. ### Claim 8 (depends on 7) The composition of claim 7 wherein the isopropyl myristate concentration is between about 1% and about 10% w/w. ### Claim 9 (depends on 7) The composition of claim 7 wherein the isopropyl myristate concentration is between about 5% and about 15% w/w. ### Claim 10 (depends on 2) The composition of claim 2, wherein the isopropyl myristate concentration is between about 1% and about 20% w/w. ### Claim 11 (depends on 10) The composition of claim 10, wherein the isopropyl myristate concentration is between about 1% and about 10% w/w. ### Claim 12 (depends on 10) The composition of claim 10, wherein the isopropyl myristate concentration is between about 5% and about 15% w/w. ### Claim 13 (depends on 1) The composition of claim 1, wherein the petroleum jelly concentration is between about 70% and about 99% w/w. ### Claim 14 (depends on 2) The composition of claim 2, wherein the petroleum jelly concentration is between about 70% and about 99% w/w. ### Claim 15 (depends on 1) The composition of claim 1, further comprising a preservative. ### Claim 16 (depends on 2) The composition of claim 2, further comprising a preservative. ### Claim 17 (depends on 1) The composition of claim 1, wherein the composition is sterile. ### Claim 18 (depends on 2) The composition of claim 2, wherein the composition is sterile. ### Claim 19 (depends on 1) The composition of claim 1, wherein the latanoprost concentration is between about 0.01% and 0.5% w/w; the isopropyl myristate concentration is between about 1% and about 10% w/w; and the petroleum jelly concentration is between about 70% and about 99% w/w. ### Claim 20 (depends on 2) The composition of claim 2, wherein the latanoprost concentration is between about 0.01% and 0.5% w/w; the isopropyl myristate concentration is between about 1% and about 10% w/w; and the petroleum jelly concentration is between about 70% and about 99% w/w.